How to buy Concord Drugs shares?

You can easily buy Concord Drugs shares in Kotak Neo by [opening a demat account](https://www.kotakneo.com/open-demat-account/) and getting the KYC documents verified online.

Concord Drugs Share Price

BSE

82.29

+1.88 (2.34%)

BSE

BSE: 538965 | Pharmaceuticals | Small Cap | as on 05 Jun, 2026 • 03:29 PM IST

Buy

Concord Drugs Annualised Returns

1 Year

▲158.77%

3 Years

▲44.56%

5 Years

▲18.46%

10 Years

▲4.48%

Concord Drugs Share Price Today

As of 6 Jun 2026, Concord Drugs share price is ₹82.3. The stock opened at ₹83 and had closed at ₹80.4 the previous day. During today’s trading session, Concord Drugs share price moved between ₹80.25 and ₹83.00, with an average price for the day of ₹81.63. Over the last 52 weeks, the stock has recorded a low of ₹29.00 and a high of ₹92.52. In terms of performance, Concord Drugs share price has increased by 9% over the past six months and has increased by 158.77% over the last year.

Concord Drugs Stock Performance

1W Return	-0.12
1Y Return	151.88
Today's Low	80.25
Prev. Close	80.41
Mkt Cap (Cr.)	108.42

1M Return	-3.23
3Y Return	199.24
52-Week High	92.52
Open	82.98
PE Ratio	104.16

6M Return	8.99
Today's High	83
52-Week Low	29
Face Value	10

Concord Drugs Share Price Chart

Concord Drugs Company background

Founded in: 1995

Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue BioAdhesive, tablets, capsules and ophthalmic preparations and Readytofill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved. The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad. State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Readytofill Pellets ensures the highest level of process integrity and product quality.The Company started with Finished Pharmaceutical Formulations and then diversified into Readytofill Pellets, to provide customers with endtoend solution to their various pharmaceutical product needs to commercial contract drug manufacturing. It is engaged in developing New products Viz MUPS (Multiple Unit Pellet System), Sustained Release, Modified Release pellets with Innovative Drug Delivery Technologies by utilizing best and latest processing machinery. It operates a state of the art, cGMP contract manufacturing FormulationFillFinish facility, providing comprehensive pharmaceutical development and manufacturing services for drug products.

Concord Drugs Financial Highlights

For the full year FY2026–2027, revenue reached ₹78.77 crore and profit touched at ₹1.06 crore.

Concord Drugs SIP Returns Calculator

Monthly

Quarterly

₹5,000

Over the past

Total Investment of ₹3,00,000

Monthly SIP of ₹5,000 would have become ₹4,94,778 in 5 years with a gain of ₹1,94,778 (+64.93%)

Start SIP

Concord Drugs Fundamental

Market Cap (in crs)

108.42

Face Value

Turnover (in lacs)

4.18

Key Metrics

Qtr Change %

183.76% Gain from 52W Low

12.7

Dividend yield 1yr %

Concord Drugs Key Financials

Loading chart...

Concord Drugs Quarterly Revenue


37.89 Cr	16.97 Cr	10.28 Cr	13.61 Cr	10.39 Cr

Concord Drugs Yearly Revenue


78.77 Cr	45.26 Cr	44.93 Cr	52.09 Cr

Concord Drugs Quarterly Net Profit/Loss


0.53 Cr	0.22 Cr	0.19 Cr	0.12 Cr	0.04 Cr

Concord Drugs Yearly Net Profit/Loss


1.06 Cr	0.34 Cr	0.47 Cr	0.99 Cr

Concord Drugs Result Highlights

Concord Drugs reported a 123.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 264.4%.
Its expenses for the quarter were up by 122.6% QoQ and 259.3% YoY.
The net profit increased 140.9% QoQ and increased 1225.0% YoY.
The earnings per share (EPS) of Concord Drugs stood at 0.47 during Q4 FY 2025-26.

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Concord Drugs Technical Analysis

Moving Averages Analysis

82.29

Current Price

Bullish Moving Averages

Bearish Moving Averages

5 EMA

81.60

10 EMA

81.30

12 EMA

81.30

20 EMA

81.20

26 EMA

81.10

50 EMA

80.30

100 EMA

78.60

200 EMA

72.70

Delivery & Volume

Loading chart...

Delivery Volume %

Day

83.10%

Week

72.90%

Month

72.00%


Day Rs	4218 Rs	5077 Rs
Week Rs	4465 Rs	6121 Rs
Month Rs	3577 Rs	4967 Rs

Resistance & Support

81.85

Pivot

Resistance

First Resistance

83.44

Second Resistance

84.60

Third Resistance

86.19

Support

First Support

80.69

Second support

79.10

Third Support

77.94

Relative Strength Index

52.98

Money Flow Index

72.95

MACD

0.21

MACD Signal

0.18

Average True Range

5.32

Average Directional Index

13.67

Rate of Change (21)

-0.44

Rate of Change (125)

1.58

Concord Drugs Peer comparison

Compare


Pharmaids Pharmaceuticals Ltd.	27.62 -0.04 (-0.14%)▼	97.41	25.6	70	27.66	-8.97%	-4.56%	-45.31%	-52.95%	-7.93%	0.00%	-9.33	48.08	1.82
Godavari Drugs Ltd.	125.05 +2.55 (+2.08%)▲	126.64	69.7	135.25	122.50	-1.61%	0.08%	71.14%	29.14%	40.21%	0.00%	30.95	48.08	1.80
Denis Chem Lab Ltd.	71.70 +0.38 (+0.53%)▲	99.50	56.1	109.25	71.32	-1.78%	-6.88%	-16.37%	-32.55%	-8.36%	3.49%	11.83	48.08	1.09
Vaishali Pharma Ltd.	7.28 +0.13 (+1.82%)▲	94.98	4.75	13.59	7.15	3.26%	-5.82%	-13.54%	-43.21%	-43.74%	0.00%	23.48	48.08	1.38
Par Drugs & Chemicals Ltd.	89.89 +3.18 (+3.67%)▲	110.61	78.05	122.43	86.71	0.90%	-0.13%	-7.18%	-10.57%	-57.71%	0.00%	8.44	48.08	0.99
Sotac Pharmaceuticals Ltd	111.00 0.00 (0.00%)▼	122.66	100	152.35	111.00	0.00%	4.72%	-14.32%	-7.50%	-14.29%	0.00%	24.94	48.08	2.12

Concord Drugs Shareholding Pattern

Promoter

54.4%

Public

45.6%

Concord Drugs Latest News

01 JUN 2026

Concord Drugs - 538965 - Announcement under Regulation 30 (LODR)-Newspaper Publication

29 MAY 2026

Concord Drugs - 538965 - Compliances-Reg.24(A)-Annual Secretarial Compliance